InterWest Venture Management’s KalVista Pharmaceuticals KALV Stock Holding History

InterWest Venture Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-388,766	Closed	-$7.38M	–	13
2020 Q4	$7.38M	Hold	388,766	–	–	0.92%	7
2020 Q3	$4.89M	Hold	388,766	–	–	1.41%	7
2020 Q2	$4.7M	Hold	388,766	–	–	3.9%	6
2020 Q1	$2.97M	Hold	388,766	–	–	3.14%	7
2019 Q4	$6.92M	Hold	388,766	–	–	2.98%	5
2019 Q3	$4.51M	Hold	388,766	–	–	1.73%	7
2019 Q2	$8.61M	Hold	388,766	–	–	2.78%	5
2019 Q1	$11.1M	Hold	388,766	–	–	10.22%	4
2018 Q4	$7.68M	Hold	388,766	–	–	10.78%	4
2018 Q3	$8.6M	Buy	388,766 +58,824	+18%	+$795K	4.2%	8
2018 Q2	$2.68M	Hold	329,942	–	–	1.13%	11
2018 Q1	$3.13M	Hold	329,942	–	–	1.32%	10
2017 Q4	$3.22M	Hold	329,942	–	–	1.1%	10
2017 Q3	$2.22M	Hold	329,942	–	–	0.58%	9
2017 Q2	$2.43M	Hold	329,942	–	–	0.57%	10
2017 Q1	$2.58M	Hold	329,942	–	–	0.55%	10
2016 Q4	$2.33M	Buy	+329,942	New	+$2.43M	0.56%	12

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

InterWest Venture Management's KALV Position: Q1 2021 in Review

InterWest Venture Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 388,766 shares — an estimated $7.38M sold.

InterWest Venture Management first reported a position in KALV in Q4 2016 and held it in 17 quarters. The position peaked at $11.1M in Q1 2019. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

InterWest Venture Management reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
InterWest Venture Management sold 388,766 KalVista Pharmaceuticals shares in Q1 2021, an estimated $7.38M.
InterWest Venture Management first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 17 quarters.
InterWest Venture Management's KalVista Pharmaceuticals position peaked at $11.1M in Q1 2019.
117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on InterWest Venture Management's 13F filing for Q1 2021, filed 15 Apr 2021.